Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Drug Resistance

  Free Subscription


Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 350 articles:
HTML format



Single Articles


    February 2025
  1. XIAO Y, Xu Y, Han W, Wang B, et al
    Sub-minimum inhibitory concentrations of Rifampicin Attenuate Methicillin-resistant Staphylococcus aureus Virulence by Suppressing SaeRS Two-Component System and Arginine metabolism-related pathways.
    Int J Antimicrob Agents. 2025 Feb 3:107459.
    PubMed     Abstract available


  2. ZHANG J, Ju Y, Li L, Hameed HMA, et al
    MtrAB two-component system is crucial for the intrinsic resistance and virulence of Mycobacterium abscessus.
    Int J Antimicrob Agents. 2025;65:107442.
    PubMed     Abstract available


  3. TEICHMANN L, Pasman R, Luitwieler S, Varriale C, et al
    Adaptation of Escherichia coli to ciprofloxacin and enrofloxacin: Differential proteomics of the SOS response and RecA-independent mechanisms.
    Int J Antimicrob Agents. 2025;65:107420.
    PubMed     Abstract available


  4. RAAIJMAKERS J, Ruth MM, Schildkraut JA, Hombergh EVD, et al
    Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system.
    Int J Antimicrob Agents. 2025;65:107423.
    PubMed     Abstract available


  5. XIANG X, Kong J, Zhang J, Zhang X, et al
    Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: Driven by KPC-2 and OmpK36 mutations.
    Int J Antimicrob Agents. 2025;65:107425.
    PubMed     Abstract available


    January 2025
  6. TRIPATHI A, Jaiswal A, Kumar D, Pandit R, et al
    Whole genome sequencing revealed high occurrence of antimicrobial resistance genes in bacteria isolated from poultry manure.
    Int J Antimicrob Agents. 2025 Jan 27:107452.
    PubMed     Abstract available


  7. EASWARAN M, Govindaraj RG, Naderi M, Brylinski M, et al
    Evaluating the antibacterial activity of engineered phage capital EF, CyrillicEcSw endolysin against multidrug-resistant Escherichia coli strain Sw1.
    Int J Antimicrob Agents. 2025;65:107395.
    PubMed     Abstract available


  8. XU L, Lu X, Li Y, Butaye P, et al
    Eliminating the tigecycline resistance RND efflux pump gene cluster tmexCD-toprJ in bacteria using CRISPR/Cas9.
    Int J Antimicrob Agents. 2025;65:107390.
    PubMed     Abstract available


  9. YANG W, Xu H, Zhao Y, Chen W, et al
    Identification of bla(KPC-90) in Klebsiella pneumoniae associated with ceftazidime-avibactam resistance and the translocation & truncation of resistant genes mediated by IS26.
    Int J Antimicrob Agents. 2025;65:107388.
    PubMed     Abstract available


  10. MATAMOROS BR, Serna C, Wedel E, Montero N, et al
    NpmC - a novel A1408 16S rRNA methyltransferase in the gut of humans and animals.
    Int J Antimicrob Agents. 2025;65:107382.
    PubMed     Abstract available


    December 2024
  11. ZHANG J, Du L, Shi Q, Li X, et al
    Aerosolized plus intravenous polymyxin B in comparison to intravenous polymyxin B alone for the management of HAP caused by carbapenem-resistant gram-negative bacteria: a prospective multicenter cohort study.
    Int J Antimicrob Agents. 2024 Dec 30:107427.
    PubMed     Abstract available


  12. WAN X, Miao R, Zhang N, Huang W, et al
    Global burden of antimicrobial resistance in lower respiratory infections in 2021: a systematic analysis.
    Int J Antimicrob Agents. 2024 Dec 27:107431.
    PubMed     Abstract available


  13. OKUMU NO, Muloi DM, Moodley A, Ochieng L, et al
    Epidemiology of antimicrobial resistant diarrheagenic Escherichia coli pathotypes from children, livestock and food in Dagoretti South, Nairobi Kenya.
    Int J Antimicrob Agents. 2024 Dec 24:107419.
    PubMed     Abstract available


  14. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Corrigendum to "Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018-2019" [International Journal of Antimicrobial Agents, 62 (2023) 1-9/106824].
    Int J Antimicrob Agents. 2024 Dec 24:107408.
    PubMed    


  15. LIU C, Leng B, Xie M, Jiang S, et al
    Comparing ceftazidime/avibactam and polymyxin B for treating carbapenem-resistant organisms infections: a propensity score-matched retrospective cohort study.
    Int J Antimicrob Agents. 2024 Dec 20:107418.
    PubMed     Abstract available


  16. SHI L, Yuan H, Xu J, Long J, et al
    The longitudinal trend and driving factors of antimicrobial resistance among Streptococcus pneumoniae worldwide.
    Int J Antimicrob Agents. 2024 Dec 20:107415.
    PubMed    


  17. PENG L, Song J, Sun H, Zhang X, et al
    Molecular investigation of an epidemic dissemination of vancomycin-resistant Enterococcus faecium sequence type 80 in Guangdong Province, China.
    Int J Antimicrob Agents. 2024 Dec 19:107412.
    PubMed     Abstract available


  18. CHUA NGS, Goh KK, Lim TP, Tang SS, et al
    Individualized Antimicrobial Therapy using Antibiotic Combination Testing and Therapeutic Drug Monitoring to Treat Carbapenem-Resistant Acinetobacter baumannii Infection.
    Int J Antimicrob Agents. 2024 Dec 19:107410.
    PubMed     Abstract available


  19. NKENE I, Alapati S, Ribeiro A, Okoliegbe I, et al
    Genomic and growth fitness study of extended-spectrum beta-lactamase-producing Escherichia coli from bloodstream infections after introduction of a national 4C antimicrobial stewardship policy in Scotland.
    Int J Antimicrob Agents. 2024;64:107380.
    PubMed     Abstract available


  20. YANG YS, Lee YL, Liu YM, Kuo CF, et al
    Acquired bla(CfxA-3) carried by a conjugative transposon or duplicated intrinsic bla(CME-3) mediates cefiderocol resistance in Elizabethkingia anophelis clinical isolates.
    Int J Antimicrob Agents. 2024;64:107378.
    PubMed     Abstract available


  21. JEAN SS, Ko WC, Liu IM, Hsieh PC, et al
    Geographic differences in susceptibility profiles of potential non-class B carbapenemase-producing Enterobacterales isolates against ceftazidime-avibactam, meropenem-vaborbactam, colistin, amikacin, gentamicin, and tigecycline: Data from the Antimicro
    Int J Antimicrob Agents. 2024;64:107363.
    PubMed     Abstract available


  22. CHEN PK, Liu CY, Kuo HY, Lee YT, et al
    Emergence of extensively-drug-resistant hypervirulent Acinetobacter baumannii isolated from patients with bacteraemia: bacterial phenotype and virulence analysis.
    Int J Antimicrob Agents. 2024;64:107358.
    PubMed     Abstract available


    November 2024
  23. YANG MJ, Li MJ, Huang LD, Zhang XW, et al
    Response regulator protein CiaR regulates the transcription of ccn-microRNAs and beta-lactam antibiotic resistance conversion of Streptococcus pneumoniae.
    Int J Antimicrob Agents. 2024 Nov 18:107387.
    PubMed     Abstract available


  24. DARWICHE FI, Hussein HM, Harb SB, Nahhal S, et al
    Investigating an outbreak of extensively drug-resistant Acinetobacter baumannii in a tertiary healthcare centre in lebanon using next-generation sequencing.
    Int J Antimicrob Agents. 2024;64:107353.
    PubMed     Abstract available


  25. NGUYEN HK, Duke MM, Grayton QE, Broberg CA, et al
    Impact of nitric oxide donors on capsule, biofilm and resistance profiles of Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107339.
    PubMed     Abstract available


  26. GENG X, Li Y, Hao R, Xu C, et al
    Isobavachalcone enhances sensitivity of colistin-resistant Klebsiella pneumoniae: In vitro and in vivo proof-of-concept studies.
    Int J Antimicrob Agents. 2024;64:107338.
    PubMed     Abstract available


  27. ZHANG F, Li Z, Liu X, Li Z, et al
    In-host intra- and inter-species transfer of bla(KPC-2) and bla(NDM-1) in Serratia marcescens and its local and global epidemiology.
    Int J Antimicrob Agents. 2024;64:107327.
    PubMed     Abstract available


    October 2024
  28. LIU W, Wang Z, Huang Y, Liu Y, et al
    Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation.
    Int J Antimicrob Agents. 2024 Oct 29:107370.
    PubMed     Abstract available


  29. OLIVA A, Curtolo A, Falletta A, Sacco F, et al
    Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients.
    Int J Antimicrob Agents. 2024 Oct 26:107365.
    PubMed     Abstract available


  30. ZHOU Y, Yang Y, Wu C, Zhou P, et al
    LuxS/AI-2 system facilitate the dissemination of antibiotic-resistant plasmids in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Oct 23:107361.
    PubMed     Abstract available


  31. CHEN Y, Li W, Liu X, Chen Y, et al
    Pharmacodynamic Target Attainment at Infection Site during Treatment of Post-Neurosurgical Ventriculitis Caused by Carbapenem-Resistant Klebsiella pneumoniae with Ceftazidime-Avibactam-Based Regimens: a case report.
    Int J Antimicrob Agents. 2024 Oct 8:107356.
    PubMed     Abstract available


  32. LIU H, Zhang Y, Zhong Z, Gong Y, et al
    Immunomodulator AS101 restores colistin susceptibility of clinical colistin-resistant Escherichia coli and Klebsiella pneumoniae in vitro and in vivo.
    Int J Antimicrob Agents. 2024;64:107285.
    PubMed     Abstract available


  33. DING P, Li H, Nan Y, Liu C, et al
    Outcome of intravenous and inhaled polymyxin B treatment in patients with multidrug-resistant gram-negative bacterial pneumonia.
    Int J Antimicrob Agents. 2024;64:107293.
    PubMed     Abstract available


  34. WAN TW, Huang YT, Lai JH, Chao QT, et al
    The emergence of transposon-driven multidrug resistance in invasive nontypeable Haemophilus influenzae over the last decade.
    Int J Antimicrob Agents. 2024;64:107319.
    PubMed     Abstract available


  35. MAJDI C, Duvauchelle V, Seghir M, Benimelis D, et al
    Investigation of PhoP response regulator inhibition to overcome resistance in Gram-negative clinical bacteria.
    Int J Antimicrob Agents. 2024;64:107298.
    PubMed    


    September 2024
  36. XU C, Zeng F, Xu Q, Yang Y, et al
    Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: a retrospective study.
    Int J Antimicrob Agents. 2024 Sep 21:107334.
    PubMed     Abstract available


  37. WU Y, Chen J, Zhang G, Li J, et al
    In vitro activities of the essential antimicrobial agents including aztreonam/avibactam, eravacycline, colistin, and other comparators against carbapenem-resistant bacteria with different carbapenemase genes: a multicenter study in China, 2021.
    Int J Antimicrob Agents. 2024 Sep 18:107341.
    PubMed     Abstract available


  38. ZHANG M, Yang S, Liu Y, Zou Z, et al
    Anti-cancer agent 5-fluorouracil reverses meropenem resistance in carbapenem-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2024 Sep 16:107337.
    PubMed     Abstract available


  39. ZENG S, Kong Q, Wu X, Duan M, et al
    Antibiotic Resistance of Helicobacter pylori in Mainland China: A Focus on Geographic Differences through Systematic Review and Meta-analysis.
    Int J Antimicrob Agents. 2024 Sep 6:107325.
    PubMed     Abstract available


  40. WEI Y, Luo H, Chen X, Yan Q, et al
    Epidemiology of subsequent Carbapenem-Resistant Enterobacterales (CRE) infection among rectal carriers: a meta-analysis of incidence, risk factors and their association with geographic region and age.
    Int J Antimicrob Agents. 2024 Sep 6:107335.
    PubMed     Abstract available


  41. WANG WY, Chiu CF, Tsao SM, Lee YL, et al
    Accurate prediction of antimicrobial resistance and genetic marker of Staphylococcus aureus clinical isolates using MALDI-TOF MS and machine learning - Across DRIAMS and Taiwan database.
    Int J Antimicrob Agents. 2024 Sep 5:107329.
    PubMed     Abstract available


  42. BULMAN ZP, Cao L, Curry BN, Biagi M, et al
    Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: a retrospective cohort study.
    Int J Antimicrob Agents. 2024 Sep 4:107321.
    PubMed     Abstract available


  43. PADASAS-ADALLA CS, Ortega-Kindica RCMH, Lomeli-Ortega CO, Tabugo SRM, et al
    A metagenomics-based approach to decipher the resistome and mobilome of two seahorse species, Hippocampus barbouri and Hippocampus comes.
    Int J Antimicrob Agents. 2024;64:107296.
    PubMed     Abstract available


  44. LIU S, Yuan D, Zhou Y, Wang B, et al
    Beware of resistance to 2nd-generation integrase inhibitors: A systematic meta-analysis of HIV-1 integrase inhibitors resistance and drug resistance mutations.
    Int J Antimicrob Agents. 2024;64:107294.
    PubMed     Abstract available


  45. ZHANG Z, Ren R, Peng C, Ji Y, et al
    Genomic characterisation of a multidrug-resistant Klebsiella pneumoniae co-harbouring bla(NDM-1), bla(KPC-2), and tet(A) isolated from the bloodstream infections of patients.
    Int J Antimicrob Agents. 2024;64:107290.
    PubMed     Abstract available


  46. ZHANG P, Hu J, Wu W, Shi W, et al
    Evolutionary adaptation of KPC-2-producing Pseudomonas aeruginosa high-risk sequence type 463 in a lung transplant patient.
    Int J Antimicrob Agents. 2024;64:107279.
    PubMed     Abstract available


  47. EUZEN V, Xhaard A, Berreira-Ibraim S, Deville L, et al
    Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant.
    Int J Antimicrob Agents. 2024;64:107281.
    PubMed     Abstract available


  48. LI P, Xu Q, Ding L, Zhang X, et al
    Q48K mutation in the type IB nitroreductase NrmA is responsible for nitrofurantoin resistance in Enterococcus faecium.
    Int J Antimicrob Agents. 2024;64:107277.
    PubMed     Abstract available


  49. JAMIN C, Notermans DW, Beuken E, Maat I, et al
    KPC-85, a carbapenemase-producing and ceftazidime-avibactam-resistant KPC-3 variant found in Klebsiella pneumoniae ST512 in the Netherlands.
    Int J Antimicrob Agents. 2024;64:107271.
    PubMed    


  50. HAN X, Yao J, He J, Liu H, et al
    Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107275.
    PubMed     Abstract available


  51. YU Y, Li X, Wu Y, Lou N, et al
    Global prevalence of fosfomycin resistance genes fosA and fosB in multidrug-resistant bacteria.
    Int J Antimicrob Agents. 2024;64:107272.
    PubMed    


  52. KURKCU MF, Yapalak ZL, Var A, Atilan K, et al
    Investigation of Mycobacterium tuberculosis complex isolates isolated from various clinical samples and their antimycobacterial resistance status: A ten-year retrospective study.
    Int J Antimicrob Agents. 2024;64:107269.
    PubMed    


  53. TANG C, Shen S, Yang W, Shi Q, et al
    Complex evolutionary trajectories in vivo of two novel KPC variants conferring ceftazidime-avibactam resistance.
    Int J Antimicrob Agents. 2024;64:107265.
    PubMed     Abstract available


  54. RODRIGUEZ-RUIZ JP, Lin Q, Van Heirstraeten L, Lammens C, et al
    Long-term effects of ciprofloxacin treatment on the gastrointestinal and oropharyngeal microbiome are more pronounced after longer antibiotic courses.
    Int J Antimicrob Agents. 2024;64:107259.
    PubMed     Abstract available


  55. TELLAPRAGADA C, Razavi M, Peris PS, Jonsson P, et al
    Resistance to aztreonam-avibactam among clinical isolates of Escherichia coli is primarily mediated by altered penicillin-binding protein 3 and impermeability.
    Int J Antimicrob Agents. 2024;64:107256.
    PubMed     Abstract available


    August 2024
  56. RAGHAVAN S, Kim KS
    Host immunomodulation strategies to combat pandemic-associated antimicrobial-resistant secondary bacterial infections.
    Int J Antimicrob Agents. 2024 Aug 19:107308.
    PubMed     Abstract available


  57. DE MEDEIROS RC, Barros Dos Santos KT, Costa-Lourenco APR, Skaf LB, et al
    Neisseria gonorrhoeae ST-1901 in Rio de Janeiro from 2006 to 2022: phylogeny and antimicrobial resistance evolution of a well-succeeded pathogen.
    Int J Antimicrob Agents. 2024 Aug 12:107299.
    PubMed     Abstract available


  58. CHOU SH, Chuang C, Juan CH, Ho YC, et al
    Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.
    Int J Antimicrob Agents. 2024;64:107244.
    PubMed     Abstract available


  59. GARCIA-FERNANDEZ S, Rodriguez-Grande J, Siller-Ruiz M, Fraile-Valcarcel N, et al
    Within-host transition to GES-55 during a GES-6-producing Serratia marcescens outbreak: Emergence of ceftazidime-avibactam resistance and increased susceptibility to carbapenems.
    Int J Antimicrob Agents. 2024;64:107257.
    PubMed     Abstract available


  60. WANG M, Hao M, Cui X, Liu M, et al
    Tracking emergence and outbreak of Klebsiella pneumoniae co-producing NDM-1 and KPC-2 after sulfamethoxazole-trimethoprim treatment: Insights from genetic analysis.
    Int J Antimicrob Agents. 2024;64:107237.
    PubMed     Abstract available


  61. LIU S, Zhou H, Kong J, Chen H, et al
    Verapamil increases susceptibility of colistin-resistant Acinetobacter baumannii to colistin.
    Int J Antimicrob Agents. 2024;64:107233.
    PubMed     Abstract available


  62. TANG C, Shen S, Yang W, Shi Q, et al
    Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla(KPC) mutation.
    Int J Antimicrob Agents. 2024;64:107228.
    PubMed     Abstract available


  63. LIAO W, Wang X, Wang Y, Ma P, et al
    Noncanonical mutations in ribosome nascent peptide exit tunnel confer clarithromycin resistance in Mycobacterium abscessus complex.
    Int J Antimicrob Agents. 2024;64:107223.
    PubMed     Abstract available


  64. WANG WX, Wu JZ, Zhang BL, Yu JY, et al
    Phage therapy combats pan drug-resistant Acinetobacter baumannii infection safely and efficiently.
    Int J Antimicrob Agents. 2024;64:107220.
    PubMed     Abstract available


  65. WU M, Dong Y, Zeng L, Lin Y, et al
    CRF08_BC subtype is more prone to ART failure and new-generation NNRTI-resistance under long-term first-line ART.
    Int J Antimicrob Agents. 2024;64:107215.
    PubMed     Abstract available


  66. LAI YC, Lin LW, Lee YL
    Emergence of ceftazidime-avibactam resistance through in-vivo bla(KPC-2) to bla(KPC-33) conversion during treatment of ST11 Klebsiella pneumoniae associated infections.
    Int J Antimicrob Agents. 2024;64:107213.
    PubMed    


  67. YANG W, Chen J, Yang F, Ji P, et al
    Identification of a novel Providencia species showing multi-drug-resistant in three patients with hospital-acquired infection.
    Int J Antimicrob Agents. 2024;64:107211.
    PubMed     Abstract available


  68. KIEFFER N, Guzman-Puche J
    The importance of genomic context in interpreting fosfomycin resistance in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;64:107210.
    PubMed    


  69. GUITART-MATAS J, Sanchez-Osuna M, Saez JL, de Frutos C, et al
    Deciphering resistance mechanisms to tigecycline and colistin in Salmonella enterica isolates from animal production.
    Int J Antimicrob Agents. 2024;64:107208.
    PubMed    


  70. HARA GL, Antik A, Aguirre S, Giuliano C, et al
    The effect of the COVID-19 pandemic on the incidence and resistance of Gram-negative bacilli and antimicrobial consumption in the intensive care units of a referral hospital in Buenos Aires.
    Int J Antimicrob Agents. 2024;64:107203.
    PubMed     Abstract available


  71. ZHUANG Y, Li X, Wu Y, Jia H, et al
    Colistin resistance landscape: insights into the global spread of mcr-carrying Gram-negative bacteria.
    Int J Antimicrob Agents. 2024;64:107207.
    PubMed    


  72. RARO OHF, Bouvier M, Kerbol A, Poirel L, et al
    MultiRapid ATB NP test for detecting concomitant susceptibility and resistance of last-resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections.
    Int J Antimicrob Agents. 2024;64:107206.
    PubMed     Abstract available


    July 2024
  73. YADAV A, Shinde PB, Mohan H, Dhar MS, et al
    Gut colonization with antibiotic resistance Escherichia coli pathobionts leads to disease severity in ulcerative colitis.
    Int J Antimicrob Agents. 2024 Jul 29:107289.
    PubMed     Abstract available


  74. TANG Y, Chen X, Liu C, Xue T, et al
    Policy Text Analysis of Antimicrobial Resistance Governance in China: A Focus on National-Level Policies.
    Int J Antimicrob Agents. 2024 Jul 29:107286.
    PubMed     Abstract available


  75. YANG X, Wang T, Zhang B, Zhang W, et al
    Clinical Outcome Assessment of Colistin Sulfate in Children with Carbapenem-Resistant Organism Infections: First Data from China.
    Int J Antimicrob Agents. 2024 Jul 11:107273.
    PubMed     Abstract available


  76. TANG Y, Yang C, Liu C, Xu Y, et al
    Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant K. pneumoniae.
    Int J Antimicrob Agents. 2024 Jul 5:107268.
    PubMed     Abstract available


  77. RANDO E, Novy E, Sangiorgi F, De Pascale G, et al
    A systematic review of the pharmacokinetics and pharmacodynamics of novel beta-lactams and beta-lactam with beta-lactamase inhibitor combinations for the treatment of pneumonia caused by carbapenem-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2024 Jul 4:107266.
    PubMed     Abstract available


  78. CLEMENTE T, Diotallevi S, Lolatto R, Gagliardini R, et al
    Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry.
    Int J Antimicrob Agents. 2024;64:107195.
    PubMed    


  79. MESCHIARI M, Asquier-Khati A, Tiseo G, Luque-Paz D, et al
    Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Int J Antimicrob Agents. 2024;64:107186.
    PubMed     Abstract available


  80. CHIU LW, Ku YE, Chan FY, Lie WN, et al
    Machine learning algorithms to predict colistin-induced nephrotoxicity from electronic health records in patients with multidrug-resistant Gram-negative infection.
    Int J Antimicrob Agents. 2024;64:107175.
    PubMed     Abstract available


    June 2024
  81. BUHL MEJ, Sunnerhagen T, Join-Lambert O, Morris T, et al
    Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag).
    Int J Antimicrob Agents. 2024 Jun 26:107241.
    PubMed     Abstract available


  82. HU L, Zhang XT, Zeng X, Xiong LX, et al
    ISAba1 mediated intrinsic chromosomal oxacillinase amplification confers carbapenem resistance in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024 Jun 22:107258.
    PubMed     Abstract available


  83. XU Y, Liu D, Han P, Wang H, et al
    Rapid inference of antibiotic resistance and susceptibility for Klebsiella pneumoniae by clinical shotgun metagenomic sequencing.
    Int J Antimicrob Agents. 2024 Jun 20:107252.
    PubMed     Abstract available


  84. LI X, Mowlaboccus S, Jackson B, Cai C, et al
    Antimicrobial Resistance Among Clinically Significant Bacteria in Wildlife: An Overlooked One Health Concern.
    Int J Antimicrob Agents. 2024 Jun 19:107251.
    PubMed     Abstract available


  85. JOSHI PR, Joshi SD, Periasamy H, Bakthavatchalam YD, et al
    Novel beta-lactam/beta-lactamase inhibitor combinations show limited activity against Indian carbapenem-resistant Pseudomonas aeruginosa isolates due to conundrum of diverse resistance mechanisms.
    Int J Antimicrob Agents. 2024 Jun 19:107249.
    PubMed    


  86. WANG S, Ma S, Sun S, Wang Q, et al
    Global evolutionary dynamics of virulence genes in ST11-KL47 carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jun 19:107245.
    PubMed     Abstract available


  87. GATTI M, Virgili G, Viale P, Pea F, et al
    Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel
    Int J Antimicrob Agents. 2024;63:107177.
    PubMed    


  88. ZHOU J, Yan G, Tang C, Liu J, et al
    Emergence of ceftazidime-avibactam resistance in bla(KPC-33)-harbouring ST11 Klebsiella pneumoniae in a paediatric patient.
    Int J Antimicrob Agents. 2024;63:107163.
    PubMed     Abstract available


  89. BREEN SKJ, Harper M, Lopez-Causape C, Rogers KE, et al
    Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Int J Antimicrob Agents. 2024;63:107161.
    PubMed     Abstract available


  90. HONG Y, Chen Y, Zhang J, Zhang H, et al
    Identification of the novel fosfomycin resistance gene fosSC in Staphylococcus capitis.
    Int J Antimicrob Agents. 2024;63:107162.
    PubMed     Abstract available


  91. ZHAO H, Li J, Feng S, Xu L, et al
    High-throughput mutagenesis and screening approach for the identification of drug-resistant mutations in the rifampicin resistance-determining region of mycobacteria.
    Int J Antimicrob Agents. 2024;63:107158.
    PubMed     Abstract available


    May 2024
  92. CHEN Q, Zhang F, Bai J, Che Q, et al
    Bacteriophage-Resistant Carbapenem-Resistant Klebsiella pneumoniae Shows Reduced Antibiotic Resistance and Virulence.
    Int J Antimicrob Agents. 2024 May 27:107221.
    PubMed     Abstract available


  93. LAI CC, Hsueh CC, Hsu CK, Tsai YW, et al
    Disease burden and macrolide resistance of Mycoplasma pneumoniae infection in adults in Asia-Pacific region.
    Int J Antimicrob Agents. 2024 May 14:107205.
    PubMed     Abstract available


  94. DE OLIVEIRA HC, Santos MDM, Camillo-Andrade AC, Castelli RF, et al
    Proteomics reveals that the antifungal activity of fenbendazole against Cryptococcus neoformans requires protein kinases.
    Int J Antimicrob Agents. 2024;63:107157.
    PubMed     Abstract available


  95. YANG W, Tang C, Shen S, Shi Q, et al
    Spread and evolution of bla(KPC)-plasmid between Serratia marcescens and Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;63:107149.
    PubMed     Abstract available


  96. LIM C, Coombs GW, Daley DA, Shoby P, et al
    Whole-genome sequencing identifies MprF mutations in a genetically diverse population of daptomycin non-susceptible Staphylococcus aureus in Australia.
    Int J Antimicrob Agents. 2024;63:107144.
    PubMed     Abstract available


  97. XU H, Tan C, Li C, Li J, et al
    ESBL-Escherichia coli extracellular vesicles mediate bacterial resistance to beta-lactam and mediate horizontal transfer of bla(CTX-M-55).
    Int J Antimicrob Agents. 2024;63:107145.
    PubMed     Abstract available


  98. MONTE DFM, de Oliveira CJB
    Silent dissemination of fosfomycin resistance genes in critical-priority Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024;63:107139.
    PubMed    


  99. LONG H, Zhao F, Feng Y, Zong Z, et al
    Global distribution of bla(CMY-42), a gene mediating reduced susceptibility to aztreonam-avibactam and ceftazidime-avibactam, in Escherichia coli.
    Int J Antimicrob Agents. 2024;63:107141.
    PubMed    


  100. MESCHIARI M, Faltoni M, Kaleci S, Tassoni G, et al
    Intravenous fosfomycin in combination regimens as a treatment option for difficult-to-treat infections due to multi-drug-resistant Gram-negative organisms: A real-life experience.
    Int J Antimicrob Agents. 2024;63:107134.
    PubMed     Abstract available


  101. MEZCORD V, Traglia GM, Pasteran F, Escalante J, et al
    Characterisation of cefiderocol-resistant spontaneous mutant variants of Klebsiella pneumoniae-producing NDM-5 with a single mutation in cirA.
    Int J Antimicrob Agents. 2024;63:107131.
    PubMed    


  102. ATHANASSA Z, Manioudaki S, Petsa I, Koumaki V, et al
    Effectiveness and safety of minocycline combination therapy for the treatment of patients with ventilator-associated pneumonia due to extensively drug- or pandrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107129.
    PubMed    


  103. WANG L, Zhou X, Lu Y, Zhang X, et al
    Levofloxacin-induced MexS mutation triggers imipenem-relebactam resistance in a KPC-producing Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2024;63:107119.
    PubMed     Abstract available


  104. HSU CK, Lai CC, Chen CC, Chen HJ, et al
    Evaluation of three brands of Mueller-Hinton media for broth microdilution method to determine the susceptibility of multidrug-resistant Gram-negative bacilli against eravacycline.
    Int J Antimicrob Agents. 2024;63:107117.
    PubMed    


  105. AMODIO E, Pizzo S, Vella G, De Francisci V, et al
    Increase of multidrug-resistant bacteria after the COVID-19 pandemic in a major teaching Hospital in Sicily (2018-2021).
    Int J Antimicrob Agents. 2024;63:107123.
    PubMed     Abstract available


    April 2024
  106. RUSSO A, Gulli SP, D'Avino A, Borrazzo C, et al
    Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter clinical experience.
    Int J Antimicrob Agents. 2024 Apr 30:107190.
    PubMed     Abstract available


  107. ZHUANG H, Chen M, Hu D, Liu L, et al
    Role of tcaA, a potential target as a ceftobiprole resistance breaker, in MRSA beta-lactam resistance.
    Int J Antimicrob Agents. 2024 Apr 29:107185.
    PubMed     Abstract available


  108. FRIMODT-MOLLER N, Hansen JU, Plattner M, Huseby DL, et al
    Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine blood stream infection models.
    Int J Antimicrob Agents. 2024 Apr 21:107181.
    PubMed     Abstract available


  109. SALLEE L, Souchet L, Boutolleau D, Nguyen S, et al
    Amenamevir for Treating Acyclovir-Resistant or Refractory Herpes Simplex Virus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Two Case Reports.
    Int J Antimicrob Agents. 2024 Apr 10:107169.
    PubMed    


  110. VO T, Pontarotti P, Rolain JM, Merhej V, et al
    Mechanisms of acquisition of vanA operon among vancomycin-resistant Staphylococcus aureus genomes: the tip of the iceberg?
    Int J Antimicrob Agents. 2024 Apr 8:107154.
    PubMed     Abstract available


  111. GILL K, Takamichi B, Cooper A
    Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: new data from CREDIBLE-CR with an updated meta-analysis.
    Int J Antimicrob Agents. 2024 Apr 4:107167.
    PubMed    


  112. GATTI M, Cosentino F, Giannella M, Viale P, et al
    In reply to the Letter to the Editor regarding "Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis".
    Int J Antimicrob Agents. 2024 Apr 4:107168.
    PubMed    


  113. MONTE DFM, de Oliveira CJB
    A 22-year Brazilian colistin resistance surveillance on Escherichia coli and Salmonella spp. originating from food-producing animals.
    Int J Antimicrob Agents. 2024;63:107114.
    PubMed    


    March 2024
  114. HU J, Zha L, Yu YW, Su Q, et al
    Efficacy of Ceftazidime-Avibactam in the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections: focus on Solid Organ Transplantation Recipients.
    Int J Antimicrob Agents. 2024 Mar 19:107152.
    PubMed     Abstract available


  115. HO LC, Yu Chi C, You YS, Hsieh YW, et al
    Impact of the implementation of the Intelligent Antimicrobial System (iAMS) on clinical outcomes among patients with bacteraemia caused by methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2024 Mar 13:107142.
    PubMed     Abstract available


    February 2024
  116. KHARAT AS, Makwana N, Nasser M, Gayen S, et al
    Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
    Int J Antimicrob Agents. 2024 Feb 29:107125.
    PubMed     Abstract available


  117. WANG C, Bai C, Chen K, Du Q, et al
    International guidelines for the treatment of carbapenem-resistant Gram-negative bacilli infections: a comparison and evaluation.
    Int J Antimicrob Agents. 2024 Feb 26:107120.
    PubMed     Abstract available


  118. BOATTINI M, Bianco G, Llorente LI, Acero LA, et al
    Enterobacterales carrying chromosomal AmpC beta-lactamases in Europe (EuESCPM): epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020-2022.
    Int J Antimicrob Agents. 2024 Feb 15:107115.
    PubMed     Abstract available


  119. YANG L, Gao Y, Zhang J, Tian C, et al
    Antimicrobial peptide DvAMP combats carbapenem-resistant Acinetobacter baumannii infection.
    Int J Antimicrob Agents. 2024 Feb 5:107106.
    PubMed     Abstract available


  120. WANG JL, Lai CC, Tsai YW, Ko WC, et al
    High ceftazidime-avibactam resistance among carbapenem-resistant Enterobacter species: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2014-2021.
    Int J Antimicrob Agents. 2024 Feb 5:107105.
    PubMed     Abstract available


  121. SIVAY MV, Maksimenko LV, Nalimova TM, Nefedova AA, et al
    HIV drug resistance among patients experiencing antiretroviral therapy failure in Russia, 2019-2021.
    Int J Antimicrob Agents. 2024;63:107074.
    PubMed     Abstract available


  122. CHEN H, Hu P, Liu H, Liu S, et al
    Combining with domiphen bromide restores colistin efficacy against colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2024;63:107066.
    PubMed     Abstract available


  123. WANG C, Zhang T, Wang Y, Wang Y, et al
    Proguanil and chlorhexidine augment the antibacterial activities of clarithromycin and rifampicin against Acinetobacter baumannii.
    Int J Antimicrob Agents. 2024;63:107065.
    PubMed     Abstract available


    January 2024
  124. FENG Y, Fang Q, Luo H, Li J, et al
    Safety and efficacy of a phage cocktail on murine wound infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2024 Jan 11:107088.
    PubMed     Abstract available


  125. HSUEH CC, Lai CC, Tsai YW, Ko WC, et al
    Poor in vitro activity of ceftazidime/avibactam against carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    Int J Antimicrob Agents. 2024 Jan 11:107087.
    PubMed    


  126. HERSHKO Y, Rannon E, Adler A, Burstein D, et al
    WarA, a remote homolog of NpmA and KamB from Nocardia wallacei, confers broad spectrum aminoglycoside resistance in Nocardia and Mycobacteria.
    Int J Antimicrob Agents. 2024 Jan 11:107089.
    PubMed     Abstract available


  127. MUSHTAQ S, Vickers A, Woodford N, Livermore DM, et al
    Activity of aztreonam/avibactam and ceftazidime/avibactam against Enterobacterales with carbapenemase-independent carbapenem resistance.
    Int J Antimicrob Agents. 2024 Jan 2:107081.
    PubMed     Abstract available


  128. RATOUIT P, Malet I, Soulie C, Denis J, et al
    HIV-1 resistance mutations to integrase inhibitors impair both integration and reverse transcription steps.
    Int J Antimicrob Agents. 2024;63:107026.
    PubMed    


  129. PARK S, Choi J, Shin D, Kwon KT, et al
    Conversion to colistin susceptibility by tigecycline exposure in colistin-resistant Klebsiella pneumoniae and its implications to combination therapy.
    Int J Antimicrob Agents. 2024;63:107017.
    PubMed     Abstract available


  130. KIM SJ, Shin JH, Kim H, Ko KS, et al
    Roles of crrAB two-component regulatory system in Klebsiella pneumoniae: growth yield, survival in initial colistin treatment stage, and virulence.
    Int J Antimicrob Agents. 2024;63:107011.
    PubMed     Abstract available


    December 2023
  131. DU Y, Wang Y, Geng J, Long J, et al
    Molecular Mechanism of Hfq-dependent sRNA1039 and sRNA1600 Regulating Antibiotic Resistance and Virulence in Shigella sonnei.
    Int J Antimicrob Agents. 2023 Dec 21:107070.
    PubMed     Abstract available


  132. YU MC, Huang CK, Hung CS, Wang CH, et al
    Emerging insight of whole genome sequencing coupled with protein structure prediction into the pyrazinamide-resistance signature of Mycobacterium tuberculosis.
    Int J Antimicrob Agents. 2023 Dec 9:107053.
    PubMed     Abstract available


  133. KIAROSTAMI K, Fernandez-Barat L, Battaglini D, Motos A, et al
    The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia.
    Int J Antimicrob Agents. 2023 Dec 8:107052.
    PubMed     Abstract available


  134. JEON E, Kim MK, Park Y
    Efficacy of the bee-venom antimicrobial peptide Osmin against sensitive and carbapenem-resistant Klebsiella pneumoniae strains.
    Int J Antimicrob Agents. 2023 Dec 8:107054.
    PubMed     Abstract available


  135. GATTI M, Cosentino F, Giannella M, Viale P, et al
    Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis.
    Int J Antimicrob Agents. 2023 Dec 5:107047.
    PubMed     Abstract available


  136. HU T, Wang S, Bing J, Zheng Q, et al
    Hotspot mutations and genomic expansion of ERG11 are major mechanisms of azole resistance in environmental and human commensal isolates of Candida tropicalis.
    Int J Antimicrob Agents. 2023;62:107010.
    PubMed     Abstract available


    November 2023
  137. WANG SH, Yang KY, Sheu CC, Lin YC, et al
    Efficacy of combination therapy with standard-dose carbapenem for treating nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii in intensive care units: a multicenter retrospective propensity score-matched study.
    Int J Antimicrob Agents. 2023 Nov 29:107044.
    PubMed     Abstract available


  138. KUANG SF, Xiang J, Chen YT, Peng XX, et al
    Exogenous pyruvate promotes gentamicin uptake to kill antibiotic-resistant Vibrio alginolyticus.
    Int J Antimicrob Agents. 2023 Nov 17:107036.
    PubMed     Abstract available


  139. MUKHOPADHYAY S, Zhang P, To KKW, Liu Y, et al
    Sequential treatment effects on phage-antibiotic synergistic application against multi-drug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106951.
    PubMed     Abstract available


    October 2023
  140. XU C, Zeng F, Huang Y, Xu Q, et al
    Clinical Efficacy of Ceftazidime/avibactam Combination Therapy for Severe Hospital-acquired Pulmonary Infections Caused by Carbapenem-Resistant and Difficult-to-Treat Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Oct 25:107021.
    PubMed     Abstract available


  141. CANTON R, Gottlieb T, Coombs GW, Woo PCY, et al
    Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
    Int J Antimicrob Agents. 2023 Oct 20:107014.
    PubMed     Abstract available


  142. YU J, Lin HH, Tseng KH, Lin YT, et al
    Prediction of methicillin-resistant Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae from flagged blood cultures by combining rapid Sepsityper MALDI-TOF mass spectra with machine learning.
    Int J Antimicrob Agents. 2023 Oct 4:106994.
    PubMed     Abstract available


  143. TAO H, Liu L, Chen X, Peng L, et al
    Coexistence of Klebsiella pneumoniae and Acinetobacter baumannii contributes to antibiotic resistance.
    Int J Antimicrob Agents. 2023 Oct 2:106993.
    PubMed    


  144. WANG Q, Peng K, Liu Z, Li Y, et al
    Genomic insights into linezolid-resistant Enterococci revealed its evolutionary diversity and poxtA copy number heterogeneity.
    Int J Antimicrob Agents. 2023;62:106929.
    PubMed     Abstract available


  145. GUILLAMET MCV, Damulira C, Atkinson A, Fraser VJ, et al
    Addition of aminoglycosides reduces recurrence of infections with multidrug-resistant Gram-negative bacilli in patients with sepsis and septic shock.
    Int J Antimicrob Agents. 2023;62:106913.
    PubMed     Abstract available


    September 2023
  146. CAI T, Novelli A, Tascini C, Stefani S, et al
    Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: a systematic review and expert opinion.
    Int J Antimicrob Agents. 2023 Sep 23:106983.
    PubMed     Abstract available


  147. LIU JY, Jia JJ, Liu M, Duan H, et al
    A novel indolylbenzoquinone compound HL-J6 suppresses biofilm formation and alpha-toxin secretion in methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2023 Sep 21:106972.
    PubMed     Abstract available


  148. CAI T, Verze P, Arcaniolo D, Pandolfo SD, et al
    ANTIBIOTIC RESISTANCE PATTERNS AMONG UROPATHOGENS IN FEMALE OUTPATIENTS AFFECTED BY UNCOMPLICATED CYSTITIS: FOCUS ON FOSFOMYCIN TROMETAMOL.
    Int J Antimicrob Agents. 2023 Sep 20:106974.
    PubMed     Abstract available


  149. WU JW, Quyen TLT, Hsieh YC, Chen YY, et al
    Investigation of carbapenem-resistant Klebsiella pneumoniae in Taiwan revealed strains co-harboring bla(NDM) and bla(OXA-48-like) and a novel plasmid co-carrying bla(NDM-1) and bla(OXA-181).
    Int J Antimicrob Agents. 2023 Sep 4:106964.
    PubMed     Abstract available


  150. SALAMA EA, Eldesouky HE, Elgammal Y, Abutaleb NS, et al
    Lopinavir and ritonavir act synergistically with azoles against Candida auris in vitro and in a mouse model of disseminated candidiasis.
    Int J Antimicrob Agents. 2023;62:106906.
    PubMed     Abstract available


  151. ZHAO J, Zhu Y, Han ML, Lu J, et al
    Model-informed dose optimisation of polymyxin-rifampicin combination therapy against multidrug-resistant Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023;62:106902.
    PubMed     Abstract available


  152. HAN Y, Zhang Y, Zeng W, Huang Z, et al
    Synergy with farnesol rejuvenates colistin activity against Colistin-resistant Gram-negative bacteria in vitro and in vivo.
    Int J Antimicrob Agents. 2023;62:106899.
    PubMed     Abstract available


  153. SHE Y, Jiang Y, Luo M, Duan X, et al
    Emergence of chromosomally located bla(CTX-M-14b) and qnrS1 in Salmonella enterica serotype Kentucky ST198 in China.
    Int J Antimicrob Agents. 2023;62:106896.
    PubMed     Abstract available


  154. WANG C, Tang B, Wu J, Jin X, et al
    Detection of mcr-1-harbouring Escherichia coli by quantum dot labelling of synthetic small peptides mimicking lipopolysaccharide receptors.
    Int J Antimicrob Agents. 2023;62:106898.
    PubMed     Abstract available


  155. ZHANG N, Shan W, Gao L, Kou SH, et al
    Repurposing the Hedgehog pathway inhibitor, BMS-833923, as a phosphatidylglycerol-selective membrane-disruptive colistin adjuvant against ESKAPE pathogens.
    Int J Antimicrob Agents. 2023;62:106888.
    PubMed     Abstract available


  156. AGYEMAN AA, Lopez-Causape C, Rogers KE, Lucas DD, et al
    Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Int J Antimicrob Agents. 2023;62:106887.
    PubMed     Abstract available


    August 2023
  157. NISHIMURA B, Escalante J, Mezcord V, Tuttobene MR, et al
    HSA-induced modifications of Ton-B dependent receptors expression in cefiderocol-exposed carbapenem-resistant Acinetobacter baumannii (CRAB).
    Int J Antimicrob Agents. 2023 Aug 17:106950.
    PubMed    


  158. JONES DC, LaMartina EL, Lewis JR, Dahl AJ, et al
    One Health and Global Health View of Antimicrobial Susceptibility through the "Eye" of Aeromonas: Systematic Review and Meta-Analysis.
    Int J Antimicrob Agents. 2023;62:106848.
    PubMed     Abstract available


    July 2023
  159. MENG H, Yang J, Niu M, Zhu H, et al
    Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteremia in children: a retrospective study.
    Int J Antimicrob Agents. 2023 Jul 25:106933.
    PubMed     Abstract available


  160. WU W, Wei S, Xue CX, Zhang W, et al
    An IncN-ST7 epidemic plasmid mediates the dissemination of carbapenem-resistant Klebsiella pneumoniae in a neonatal intensive care unit over 10 years, China.
    Int J Antimicrob Agents. 2023 Jul 9:106921.
    PubMed     Abstract available


  161. DANESHNIA F, Arastehfar A, Lombardi L, Binder U, et al
    Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance.
    Int J Antimicrob Agents. 2023;62:106831.
    PubMed     Abstract available


  162. YANG S, Peng X, Ren B, Luo Y, et al
    Small molecule II-6s synergises with fluconazole against Candida albicans.
    Int J Antimicrob Agents. 2023;62:106820.
    PubMed     Abstract available


    June 2023
  163. JIANG M, Li X, Xie CL, Chen P, et al
    Fructose enabled killing of antibiotic-resistant Salmonella Enteritidis by gentamicin: Insight from reprogramming metabolomics.
    Int J Antimicrob Agents. 2023 Jun 27:106907.
    PubMed     Abstract available


  164. CHOI MH, Kim D, Lee KH, Cho JH, et al
    Changes in the prevalence of hospital-acquired pneumonia-causing bacterial pathogens and the impact of their antimicrobial resistance patterns on clinical outcomes: A propensity score-matched study.
    Int J Antimicrob Agents. 2023 Jun 19:106886.
    PubMed     Abstract available


  165. SHENKUTIE AM, Gebrelibanos D, Yao M, Hundie GB, et al
    Impairment of novel non-coding small RNA00203 inhibits biofilm formation and reduces biofilm-specific antibiotic resistance in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2023 Jun 12:106889.
    PubMed     Abstract available


  166. KOLLEF M, Dupont H, Greenberg DE, Viale P, et al
    The prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: review of the evidence.
    Int J Antimicrob Agents. 2023 Jun 8:106882.
    PubMed     Abstract available


  167. QIAO L, Zuo W, Yang Y, Liu X, et al
    Clinical Outcomes and Safety of Intravenous Polymyxin B-based Treatment in Critically Ill Patients with Carbapenem-resistant Acinetobacter baumannii Nosocomial Pneumonia.
    Int J Antimicrob Agents. 2023 Jun 8:106880.
    PubMed     Abstract available


  168. CHEN CL, Janapatla RP, Dudek A, Chen YR, et al
    Functional characterization and clinical implication of a novel epidemic carbapenem-resistant Acinetobacter baumannii genetic marker.
    Int J Antimicrob Agents. 2023 Jun 6:106879.
    PubMed     Abstract available


  169. HU H, Shi Q, Zhang P, Quan J, et al
    Prevalence and molecular characteristics of colistin-resistant isolates among clinically isolated carbapenem-resistant Klebsiella pneumoniae in China.
    Int J Antimicrob Agents. 2023 Jun 3:106873.
    PubMed     Abstract available


    May 2023
  170. QU J, Xu J, Liu Y, Hu C, et al
    Real world effectiveness of ceftazidime/avibactam versus polymyxin B in treating patients with carbapenem-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2023 May 27:106872.
    PubMed     Abstract available


  171. DING L, Guo Y, Hu F
    Antimicrobial Resistance Surveillance: China's nearly 40-Year Effort.
    Int J Antimicrob Agents. 2023 May 25:106869.
    PubMed    


  172. GATTI M, Rinaldi M, Tonetti T, Gaibani P, et al
    Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
    Int J Antimicrob Agents. 2023 May 14:106852.
    PubMed     Abstract available


  173. GARCIA P, Moscoso M, Fernandez MC, Fuentes-Valverde V, et al
    Comparison of the in vivo efficacy of the ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
    Int J Antimicrob Agents. 2023 May 5:106836.
    PubMed     Abstract available


  174. YANG Q, Zhu Y, Schwarz S, Wang L, et al
    Integrative and conjugative elements in streptococci can act as vectors for plasmids and translocatable units integrated via IS1216E.
    Int J Antimicrob Agents. 2023;61:106793.
    PubMed     Abstract available


  175. KARLOWSKY JA, Lob SH, Siddiqui F, Akrich B, et al
    In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020.
    Int J Antimicrob Agents. 2023;61:106772.
    PubMed     Abstract available


  176. LAFFONT-LOZES P, Salipante F, Leguelinel-Blache G, Dunyach-Remy C, et al
    Effect of antimicrobial consumption on Escherichia coli resistance: assessment and forecasting using Dynamic Regression models in a French university hospital (2014-2019).
    Int J Antimicrob Agents. 2023;61:106768.
    PubMed     Abstract available


  177. JEAN SS, Liu IM, Hsieh PC, Kuo DH, et al
    Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Int J Antimicrob Agents. 2023;61:106763.
    PubMed     Abstract available


    April 2023
  178. CAI J, Chen M, Liu Q, Luo J, et al
    Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China.
    Int J Antimicrob Agents. 2023 Apr 29:106835.
    PubMed     Abstract available


  179. PLANKAOVA A, Brajerova M, Capek V, Novotna GB, et al
    Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant C. difficile ribotypes 176 and 001 in Slovakia in 2018-2019.
    Int J Antimicrob Agents. 2023 Apr 26:106824.
    PubMed     Abstract available


  180. RUSSO A, Bruni A, Gulli S, Borrazzo C, et al
    Efficacy of cefiderocol- versus colistin-containing regimen for treatment of bacteremic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in COVID-19 patients.
    Int J Antimicrob Agents. 2023 Apr 21:106825.
    PubMed     Abstract available


  181. HONDA H, Goto T, Uehara Y, Takamatsu A, et al
    Promotion of antimicrobial stewardship following the issuance of the antimicrobial resistance national action plan in Japan: a systematic review of 2016 to 2020.
    Int J Antimicrob Agents. 2023 Apr 21:106829.
    PubMed     Abstract available


  182. DE LA FUENTE C, Rodriguez M, Merino N, Carmona P, et al
    Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria.
    Int J Antimicrob Agents. 2023 Apr 14:106818.
    PubMed     Abstract available


  183. ZAKHOUR J, Haddad SF, Kerbage A, Heiman W, et al
    Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Apr 13:106816.
    PubMed     Abstract available


  184. CHANG CY, Lee YL, Huang YT, Ko WC, et al
    In vitro activity of imipenem/relebactam, meropenem/vaborbactam and comparators against Enterobacterales causing urinary tract infection in Taiwan: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2020.
    Int J Antimicrob Agents. 2023 Apr 12:106815.
    PubMed     Abstract available


  185. TRECARICHI EM, Giuliano G, Cattaneo C, Ballanti S, et al
    Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey.
    Int J Antimicrob Agents. 2023 Apr 6:106806.
    PubMed     Abstract available


  186. JO J, Park W, Kweon DH, Ko KS, et al
    Development mechanism of resistant population post-exposure to tigecycline in tigecycline-heteroresistant Acinetobacter baumannii strain.
    Int J Antimicrob Agents. 2023;61:106739.
    PubMed     Abstract available


  187. EINAV S, Leone M, Martin-Loeches I
    Sepsis and antibiotics: When should we deploy a parachute?
    Int J Antimicrob Agents. 2023;61:106732.
    PubMed     Abstract available


    March 2023
  188. YU J, Lin YT, Chen WC, Tseng KH, et al
    Direct prediction of carbapenem-resistant, carbapenemase-producing, and colistin-resistant Klebsiella pneumoniae isolates from routine MALDI-TOF mass spectra using machine learning and outcome evaluation.
    Int J Antimicrob Agents. 2023 Mar 31:106799.
    PubMed     Abstract available


  189. FORTUNATO G, Vaz-Moreira I, Gajic I, Manaia CM, et al
    Insight into phylogenomic bias of bla(VIM-2) or bla(NDM-1) dissemination amongst carbapenem resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2023 Mar 14:106788.
    PubMed     Abstract available


  190. XIU L, Wang L, Li Y, Hu L, et al
    Multicentre Clinical Evaluation of a Molecular Diagnostic Assay to Identify Neisseria gonorrhoeae Infection and Detect Antimicrobial Resistance.
    Int J Antimicrob Agents. 2023 Mar 12:106785.
    PubMed     Abstract available


  191. ZHAO X, Li S, Zhang Y, Wang J, et al
    Ceftazidime-avibactam-based combination therapy for hospital-acquired central nervous system infections caused by carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Mar 9:106777.
    PubMed     Abstract available


  192. SALADINI F, Giammarino F, Maggiolo F, Ferrara M, et al
    Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    Int J Antimicrob Agents. 2023;61:106737.
    PubMed     Abstract available


  193. HAGHANI I, Yahyazadeh Z, Hedayati MT, Shokohi T, et al
    Antifungal activity of miltefosine against both azole-susceptible and -resistant Aspergillus strains.
    Int J Antimicrob Agents. 2023;61:106715.
    PubMed     Abstract available


    February 2023
  194. CATTEAU L, Iglesias YD, Tsunemoto H, Pogliano J, et al
    Nafcillin Augmentation of Daptomycin and Cathelicidin LL-37 Killing of Methicillin-resistant Staphylococcus epidermidis: Foundations of Successful Therapy of Endocarditis.
    Int J Antimicrob Agents. 2023 Feb 10:106758.
    PubMed     Abstract available


  195. PU D, Zhao J, Lu B, Zhang Y, et al
    Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2023 Feb 7:106747.
    PubMed     Abstract available


  196. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    National surveillance of antimicrobial susceptibilities to ceftaroline, dalbavancin, telavancin, tedizolid, eravacycline, omadacycline, and other comparator antibiotics and genetic characteristics of bacteremic Staphylococcus aureus isolates in adults
    Int J Antimicrob Agents. 2023 Feb 7:106745.
    PubMed     Abstract available


  197. YU W, Zhang H, Zhu Y, Jia P, et al
    In vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa collected in the Study for Monitoring Antimicrobial Resistance Trends (SMART) between 2016-2019 in China.
    Int J Antimicrob Agents. 2023 Feb 1:106741.
    PubMed     Abstract available


  198. KARRULI A, Massa A, Andini R, Marrazzo T, et al
    Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
    Int J Antimicrob Agents. 2023;61:106723.
    PubMed     Abstract available


  199. HUMPHRIES RM, Janssen H, Hey-Hadavi JH, Hackel M, et al
    Multidrug-resistant Gram-negative bacilli recovered from respiratory and blood specimens from adults: the ATLAS surveillance program in European hospitals, 2018-2020.
    Int J Antimicrob Agents. 2023;61:106724.
    PubMed     Abstract available


    January 2023
  200. PATEL D, Brown ML, Edwards S, Oster RA, et al
    Outcomes of Daptomycin Plus Ceftaroline Versus Alternative Therapy for Persistent Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia.
    Int J Antimicrob Agents. 2023 Jan 20:106735.
    PubMed     Abstract available


  201. MALIN JJ, von Wintersdorff CJH, Penders J, Savelkoul PHM, et al
    Longitudinal fluctuations of common antimicrobial resistance genes in the gut microbiomes of healthy Dutch individuals.
    Int J Antimicrob Agents. 2023 Jan 11:106716.
    PubMed     Abstract available


  202. RHOUMA M, Madec JY, Laxminarayan R
    Colistin: From the shadows to a One Health approach for addressing antimicrobial resistance.
    Int J Antimicrob Agents. 2023 Jan 11:106713.
    PubMed     Abstract available


  203. CHEN CH, Wu PH, Lu MC, Ho MW, et al
    Geographic patterns of carbapenem-resistant, multidrug-resistant, and difficult-to-treat Acinetobacter baumannii in the Asia-Pacific Region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
    Int J Antimicrob Agents. 2023 Jan 3:106707.
    PubMed     Abstract available


  204. NYAMANKOLLY E, Bellecave P, Wittkop L, Le Marec F, et al
    Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
    Int J Antimicrob Agents. 2023;61:106696.
    PubMed     Abstract available


    December 2022
  205. MEZCORD V, Wong O, Pasteran F, Corso A, et al
    Role of beta-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.
    Int J Antimicrob Agents. 2022 Dec 2:106700.
    PubMed    


  206. GATTI M, Pascale R, Cojutti PG, Rinaldi M, et al
    A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime/avibactam in a case series of renal critically ill patients treated for documented carbapenem-resistant Gram-negative bloodstream infections and/or ventilator-as
    Int J Antimicrob Agents. 2022 Dec 1:106699.
    PubMed     Abstract available


    November 2022
  207. WOHLFARTH E, Kresken M, Higgins PG, Stefanik D, et al
    The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.
    Int J Antimicrob Agents. 2022 Nov 11:106689.
    PubMed     Abstract available


  208. KAMUS L, Auger G, Gambarotto K, Houivet J, et al
    Investigation of a vanA linezolid- and vancomycin-resistant Enterococcus faecium outbreak in the Southwest Indian Ocean (Reunion Island).
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  209. GUENEAU R, Joannard B, Haddad N, Alby F, et al
    Extensive dermatophytosis caused by terbinafine-resistant Trichophyton indotineae, successfully treated with topical voriconazole.
    Int J Antimicrob Agents. 2022;60.
    PubMed    


  210. FAN F, Liu Y, Liu Y, Lv R, et al
    Candida albicans biofilms: antifungal resistance, immune evasion, and emerging therapeutic strategies.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  211. GEUSAU A, Chromy D, Heissenberger D, Lippert K, et al
    Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a phenotypic and genetic characterization from 2013 to 2020.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


  212. WANG P, Liu D, Sun T, Zhang X, et al
    Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2022;60.
    PubMed     Abstract available


    October 2022
  213. HUANG YS, Sun HY, Chang SY, Chuang YC, et al
    Virological Responses to Tenofovir Alafenamide-Containing Antiretroviral Therapy in People Living with HIV Who Had Lamivudine-Resistant and Lamivudine-Susceptible Hepatitis B Virus Coinfection.
    Int J Antimicrob Agents. 2022 Oct 21:106682.
    PubMed     Abstract available


  214. TANG R, Luo R, Tang S, Song H, et al
    Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2022 Oct 21:106684.
    PubMed     Abstract available


  215. LEE YL, Ko WC, Hsueh PR
    Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Survei
    Int J Antimicrob Agents. 2022 Oct 11:106679.
    PubMed     Abstract available


  216. ANTONELLI A, Coppi M, Tellapragada C, Hasan B, et al
    Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2022;60:106668.
    PubMed     Abstract available


  217. PHUADRAKSA T, Wichit S, Arikit S, Songtawee N, et al
    Co-occurrence of mcr-2 and mcr-3 genes on chromosome of multidrug-resistant Escherichia coli isolated from healthy individuals in Thailand.
    Int J Antimicrob Agents. 2022;60:106662.
    PubMed     Abstract available


  218. GYSIN M, Hon PY, Tan P, Sengduangphachanh A, et al
    Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
    Int J Antimicrob Agents. 2022;60:106659.
    PubMed     Abstract available


  219. LAN P, Lu Y, Jiang Y, Wu X, et al
    Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2022;60:106646.
    PubMed     Abstract available


  220. ZHOU H, Wang S, Wu Y, Dong N, et al
    Carriage of the mcr-9 and mcr-10 genes in clinical strains of the Enterobacter cloacae complex in China: a prevalence and molecular epidemiology study.
    Int J Antimicrob Agents. 2022;60:106645.
    PubMed     Abstract available


    September 2022
  221. LU Y, Liu JH, Yue C, Bergen PJ, et al
    Overexpression of mcr-1 disrupts cell envelope synthesis and causes the dysregulation of carbon metabolism, redox balance and nucleic acids.
    Int J Antimicrob Agents. 2022;60:106643.
    PubMed     Abstract available


  222. STELLA G, Volpicelli L, Carlo DD, Vicenti I, et al
    Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
    Int J Antimicrob Agents. 2022;60:106636.
    PubMed     Abstract available


  223. KANJ SS, Bassetti M, Kiratisin P, Rodrigues C, et al
    Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2022;60:106633.
    PubMed     Abstract available


    August 2022
  224. SIMITSOPOULOU M, Kadiltzoglou P, Antachopoulos C, Roilides E, et al
    Daptomycin exerts differential immunomodulatory effects on host responses against methicillin-resistant Staphylococcus aureus biofilms.
    Int J Antimicrob Agents. 2022 Aug 26:106666.
    PubMed     Abstract available


  225. HAJ CE, Benavent E, Sierra Y, Soldevila L, et al
    Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2022 Aug 21:106664.
    PubMed     Abstract available


  226. YEH TK, Lin HJ, Liu PY, Wang JH, et al
    Antibiotic resistance in Enterobacter hormaechei.
    Int J Antimicrob Agents. 2022 Aug 4:106650.
    PubMed     Abstract available


  227. WANG X, Wang Y, Jiang X, Gong X, et al
    Co-transfer of mcr-8 with blaNDM-1 or tmexCD1-toprJ1 by plasmid hybridisation.
    Int J Antimicrob Agents. 2022;60:106619.
    PubMed     Abstract available


  228. TISEO G, Brigante G, Giacobbe DR, Maraolo AE, et al
    Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrob
    Int J Antimicrob Agents. 2022;60:106611.
    PubMed     Abstract available


  229. SACCO F, Raponi G, Oliva A, Bibbolino G, et al
    An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and blaNDM: evaluation of the global dissemination of these resistance determinants.
    Int J Antimicrob Agents. 2022;60:106615.
    PubMed     Abstract available


    June 2022
  230. XIE M, Chen K, Chan EW, Zhang R, et al
    Characterization of clinical carbapenem-resistant K1 Klebsiella quasipneumoniae subsp. similipneumoniae strains harboring virulence plasmid.
    Int J Antimicrob Agents. 2022 Jun 24:106628.
    PubMed     Abstract available


  231. JUAN CH, Chou SH, Chen IR, Yang CI, et al
    Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant Klebsiella pneumoniae strains upon hospital admission in a general ward in Taiwan.
    Int J Antimicrob Agents. 2022 Jun 18:106624.
    PubMed     Abstract available


  232. JEAN SS, Lee YL, Hsu CW, Hsueh PR, et al
    In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-beta-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership
    Int J Antimicrob Agents. 2022 Jun 16:106617.
    PubMed     Abstract available


  233. BEMER P, Aubry A, Tessier E, d'Epenoux LR, et al
    Emergence of methicillin resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University French Hospital.
    Int J Antimicrob Agents. 2022 Jun 9:106613.
    PubMed    


  234. ZHOU ZL, Tseng KY, Chen YZ, Tsai DJ, et al
    Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018.
    Int J Antimicrob Agents. 2022;59:106592.
    PubMed     Abstract available


  235. ELIAS R, Spadar A, Phelan J, Melo-Cristino J, et al
    A phylogenomic approach for the analysis of colistin resistance-associated genes in Klebsiella pneumoniae, its mutational diversity and implications for phenotypic resistance.
    Int J Antimicrob Agents. 2022;59:106581.
    PubMed     Abstract available


    May 2022
  236. KIM JH, Kim TS, Chang E, Kang CK, et al
    Effectiveness of antimicrobial stewardship programmes based on rapid antibiotic susceptibility testing of haematologic patients having high-risk factors for bacteraemia related mortality: A post-hoc analysis of an RCT.
    Int J Antimicrob Agents. 2022 May 16:106604.
    PubMed     Abstract available


  237. YU Y, Zhao H, Lin J, Li Z, et al
    Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria.
    Int J Antimicrob Agents. 2022;59:106582.
    PubMed     Abstract available


  238. LIAO W, Cui Y, Quan J, Zhao D, et al
    High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade.
    Int J Antimicrob Agents. 2022;59:106573.
    PubMed     Abstract available


    April 2022
  239. KOMEDA T, Shrestha S, Sherchan JB, Tohya M, et al
    Emergence of a highly colistin-resistant Aeromonas jandaei clinical isolate harbouring four genes encoding phosphoethanolamine transferases in Nepal.
    Int J Antimicrob Agents. 2022;59:106544.
    PubMed     Abstract available


    March 2022
  240. XU T, Zhou F, Wang L, Wu S, et al
    Metronidazole-Resistant Clostridioides difficile: Genomic and Transcriptomic Traits Acquired under In vitro Metronidazole Induction.
    Int J Antimicrob Agents. 2022 Mar 13:106570.
    PubMed     Abstract available


  241. JOZEFIKOVA A, Valcek A, Soltys K, Novakova E, et al
    Persistence and multi-ward dissemination of vancomycin resistant Enterococcus faecium ST17 clone in hospital settings in Slovakia from 2017 to 2020.
    Int J Antimicrob Agents. 2022 Mar 7:106561.
    PubMed     Abstract available


  242. BALANDIN B, Ballesteros D, Pintado V, Soriano-Cuesta C, et al
    Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
    Int J Antimicrob Agents. 2022;59:106536.
    PubMed     Abstract available


  243. AHMADI A, Mohammadnejadi E, Karami P, Razzaghi-Asl N, et al
    Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016-2020).
    Int J Antimicrob Agents. 2022;59:106518.
    PubMed     Abstract available


    February 2022
  244. ASLAN AT, Kirbas E, Sancak B, Tanriverdi ES, et al
    A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Int J Antimicrob Agents. 2022 Feb 14:106554.
    PubMed     Abstract available


  245. WANG J, Jiang Y, Ji RY, Wang ZY, et al
    Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China.
    Int J Antimicrob Agents. 2022;59:106504.
    PubMed    


  246. FONSECA EL, Morgado SM, Caldart RV, Freitas F, et al
    Emergence of a VIM-2-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa ST309 in South America: a comparative genomic analysis.
    Int J Antimicrob Agents. 2022;59:106507.
    PubMed     Abstract available


  247. NANG SC, Li M, Harper M, Mandela E, et al
    Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli.
    Int J Antimicrob Agents. 2022;59:106505.
    PubMed     Abstract available


  248. GUZMAN-PUCHE J, Perez-Nadales E, Perez-Vazquez M, Causse M, et al
    In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Int J Antimicrob Agents. 2022;59:106524.
    PubMed     Abstract available


    January 2022
  249. HUANG YC, Chen CJ
    USA 300 (sequence type 8) became a major clone of methicillin-resistant Staphylococcus aureus in northern Taiwan.
    Int J Antimicrob Agents. 2022 Jan 25:106534.
    PubMed     Abstract available


  250. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available


  251. WANG WY, Hsueh PR, Tsao SM
    Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility.
    Int J Antimicrob Agents. 2022 Jan 15:106525.
    PubMed     Abstract available


  252. ARMENIA D, Santoro MM, Bellocchi MC, Carioti L, et al
    Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.
    Int J Antimicrob Agents. 2022;59:106492.
    PubMed     Abstract available


  253. PAN Y, Zeng Z, Niu H, Huang L, et al
    Whole-genome epidemiology and characterisation of mcr-1-encoding Escherichia coli in aquatic bird farms from the Pearl River Delta, China, 2019-2020.
    Int J Antimicrob Agents. 2022;59:106478.
    PubMed     Abstract available


  254. KAWAMOTO Y, Kaku N, Akamatsu N, Sakamoto K, et al
    The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan.
    Int J Antimicrob Agents. 2022;59:106480.
    PubMed     Abstract available


  255. YEH TK, Jean SS, Lee YL, Lu MC, et al
    Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
    Int J Antimicrob Agents. 2022;59:106475.
    PubMed     Abstract available


  256. LUO YC, Hsieh YC, Wu JW, Quyen TLT, et al
    Exploring the association between capsular types, sequence types, and carbapenemase genes in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2022;59:106470.
    PubMed     Abstract available


  257. ARCA-SUAREZ J, Rodino-Janeiro BK, Perez A, Guijarro-Sanchez P, et al
    Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.
    Int J Antimicrob Agents. 2022;59:106456.
    PubMed     Abstract available


    December 2021
  258. LEE SS, Cheng KF, Wong NS, Kwan CK, et al
    The emergence of antibiotic resistant Mycoplasma genitalium as the cause of non-gonococcal urethritis in male sexually transmitted infection clinic patients.
    Int J Antimicrob Agents. 2021 Dec 28:106510.
    PubMed     Abstract available


  259. WEI L, Feng Y, Wen H, Ya H, et al
    NDM-5-producing carbapenem-resistant Klebsiella pneumoniae of sequence type 789 emerged as a threat for neonates: a multi-center genome-based study.
    Int J Antimicrob Agents. 2021 Dec 24:106508.
    PubMed     Abstract available


  260. GARZA M, Mohan CV, Brunton L, Wieland B, et al
    Typology of interventions for antimicrobial use and antimicrobial resistance in aquaculture systems in LMICs.
    Int J Antimicrob Agents. 2021 Dec 9:106495.
    PubMed     Abstract available


  261. WESTERHOLT M, Hasman H, Hansen DS, Roer L, et al
    Screening patients at admission to Copenhagen hospitals for carriage of resistant bacteria after contact with healthcare systems abroad, 2016-2019.
    Int J Antimicrob Agents. 2021;58:106452.
    PubMed     Abstract available


  262. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021;58:106448.
    PubMed     Abstract available


  263. RECIO R, Viedma E, Gonzalez-Bodi S, Villa J, et al
    Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
    Int J Antimicrob Agents. 2021;58:106450.
    PubMed     Abstract available


  264. YOSHIKAWA Y, Feldhaus I, Ozcelik E, Hashiguchi TCO, et al
    Financial strategies targeting healthcare providers to promote the prudent use of antibiotics: a systematic review of the evidence.
    Int J Antimicrob Agents. 2021;58:106446.
    PubMed     Abstract available


    November 2021
  265. SEIFERT H, von Linstow ML, Janssen H, Dowzicky M, et al
    Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013-2018 Compared to 2004-2012: Results from the ATLAS Surveillance Study.
    Int J Antimicrob Agents. 2021;58:106441.
    PubMed     Abstract available


  266. CEBRIAN R, Xu C, Xia Y, Wu W, et al
    The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo.
    Int J Antimicrob Agents. 2021;58:106434.
    PubMed     Abstract available


  267. ZHU C, Li C, Lai CKC, Ng R, et al
    Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
    Int J Antimicrob Agents. 2021;58:106430.
    PubMed     Abstract available


  268. GIUFRE M, Mazzolini E, Cerquetti M, Brusaferro S, et al
    Extended-spectrum beta-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a 'One Health' study.
    Int J Antimicrob Agents. 2021;58:106433.
    PubMed     Abstract available


  269. RODRIGUEZ-SANTIAGO J, Cornejo-Juarez P, Silva-Sanchez J, Garza-Ramos U, et al
    Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas.
    Int J Antimicrob Agents. 2021;58:106426.
    PubMed     Abstract available


  270. LENZI MH, Martins WM, Roch M, Ramos PL, et al
    A new mutation in mgrb mediating polymyxin resistance in Klebsiella variicola.
    Int J Antimicrob Agents. 2021;58:106424.
    PubMed     Abstract available


    October 2021
  271. BOAS DO PRADO GV, Mendes ET, Martins RCR, Perdigao-Neto LV, et al
    Phenotypic and genotypic characteristics of a Carbapenem-resistant Serratia marcescens cohort and outbreak: describing an opportunistic pathogen.
    Int J Antimicrob Agents. 2021 Oct 26:106463.
    PubMed     Abstract available


  272. UDE Z, Flothkotter N, Sheehan G, Brennan M, et al
    Multi-Targeted Metallo-Ciprofloxacin Derivatives Rationally Designed and Developed to Overcome Antimicrobial Resistance.
    Int J Antimicrob Agents. 2021 Oct 10:106449.
    PubMed     Abstract available


  273. CHEN T, Fu Y, Hua X, Xu Q, et al
    Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections.
    Int J Antimicrob Agents. 2021;58:106404.
    PubMed     Abstract available


  274. MILTGEN G, Bour M, Allyn J, Allou N, et al
    Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area.
    Int J Antimicrob Agents. 2021;58:106402.
    PubMed     Abstract available


  275. SALVATO RS, Reis AJ, Schiefelbein SH, Gomez MAA, et al
    Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil.
    Int J Antimicrob Agents. 2021;58:106401.
    PubMed     Abstract available


    September 2021
  276. MAGALLON J, Vu P, Reeves C, Kwan S, et al
    Amikacin in combination with zinc pyrithione prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2021 Sep 19:106442.
    PubMed    


  277. CASTANHEIRA M, Doyle TB, Deshpande LM, Mendes RE, et al
    Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals.
    Int J Antimicrob Agents. 2021 Sep 18:106439.
    PubMed     Abstract available


  278. RUSSO A, Venditti M
    Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp: a case series.
    Int J Antimicrob Agents. 2021 Sep 12:106432.
    PubMed    


  279. FOLETTO VS, da Rosa TF, Serafin MB, Bottega A, et al
    Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review.
    Int J Antimicrob Agents. 2021;58:106380.
    PubMed     Abstract available


  280. MULDER M, Arp PP, Kiefte-de Jong JC, Uitterlinden AG, et al
    Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly.
    Int J Antimicrob Agents. 2021;58:106388.
    PubMed     Abstract available


  281. MORENO-MINGORANCE A, Espinal P, Rodriguez V, Goterris L, et al
    Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015-2019.
    Int J Antimicrob Agents. 2021;58:106378.
    PubMed     Abstract available


  282. FRATONI AJ, Kuti JL, Nicolau DP
    Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
    Int J Antimicrob Agents. 2021;58:106395.
    PubMed    


  283. FUENTES-CASTILLO D, Shiva C, Lincopan N, Sano E, et al
    Global high-risk clone of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae ST307 emerging in livestock in Peru.
    Int J Antimicrob Agents. 2021;58:106389.
    PubMed    


    August 2021
  284. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: High prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021 Aug 12:106418.
    PubMed     Abstract available


  285. ALLEN GP, Deao KM, Hill SA, Schipelliti SM, et al
    In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
    Int J Antimicrob Agents. 2021 Aug 12:106417.
    PubMed     Abstract available


  286. IWU CD, Patrick SM
    An insight into the Implementation of the Global Action Plan on Antimicrobial Resistance in the WHO African Region: A Roadmap for Action.
    Int J Antimicrob Agents. 2021 Aug 6:106411.
    PubMed     Abstract available


  287. LU S, Li D, Wang L, Bi Y, et al
    Promoter variations associated with expression of mcr-1 gene and level of colistin resistance.
    Int J Antimicrob Agents. 2021;58:106371.
    PubMed     Abstract available


  288. LI J, Roberts J
    Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
    Int J Antimicrob Agents. 2021;58:106369.
    PubMed    


  289. JUNCO SJ, Bowman MC, Turner RB
    Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Int J Antimicrob Agents. 2021;58:106367.
    PubMed     Abstract available


  290. RAO GG, Landersdorfer CB
    Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Int J Antimicrob Agents. 2021;58:106368.
    PubMed     Abstract available


    July 2021
  291. WARETH G, Linde J, Hammer P, Nguyen NH, et al
    Corrigendum to "Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam" [International Journal of Antimicrobial Agents, Volume 56, Issue 4, October 2020, 1061
    Int J Antimicrob Agents. 2021 Jul 26:106407.
    PubMed    


  292. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    Erratum to "Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review" [International Journal of Antimicrobial Agents (2021) Volume 58, Issue 1/106364].
    Int J Antimicrob Agents. 2021 Jul 14:106396.
    PubMed    


  293. ANTONELLO RM, Di Bella S, Betts J, La Ragione R, et al
    Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales.
    Int J Antimicrob Agents. 2021;58:106362.
    PubMed     Abstract available


  294. LAI CC, Yu WL
    Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998-2019.
    Int J Antimicrob Agents. 2021;58:106354.
    PubMed     Abstract available


    June 2021
  295. LEE YL, Ko WC, Lee WS, Lu PL, et al
    In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Res
    Int J Antimicrob Agents. 2021 Jun 21:106377.
    PubMed     Abstract available


  296. CHAIYACHAT P, Chaiprasert A, Nonghanphithak D, Smithtikarn S, et al
    Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance.
    Int J Antimicrob Agents. 2021 Jun 20:106385.
    PubMed     Abstract available


  297. MOOR J, Aebi S, Rickli S, Mostacci N, et al
    Dynamics of extended-spectrum cephalosporin-resistant E. coli in pig farms: A longitudinal study.
    Int J Antimicrob Agents. 2021 Jun 19:106382.
    PubMed     Abstract available


  298. TIMMERMANS M, Wattiau P, Denis O, Boland C, et al
    Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012-2016.
    Int J Antimicrob Agents. 2021;57:106350.
    PubMed     Abstract available


  299. CLERICI D, Oltolini C, Greco R, Ripa M, et al
    The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Int J Antimicrob Agents. 2021;57:106335.
    PubMed     Abstract available


  300. ALMANGOUR TA, Garcia E, Zhou Q, Forrest A, et al
    Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Int J Antimicrob Agents. 2021;57:106328.
    PubMed     Abstract available


    May 2021
  301. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    What is the impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries? A systematic review: AR after mass/systematic antibiotic administration.
    Int J Antimicrob Agents. 2021 May 24:106364.
    PubMed     Abstract available


  302. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available


  303. TSAI HY, Lee YL, Liu PY, Lu MC, et al
    Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Re
    Int J Antimicrob Agents. 2021 May 4:106353.
    PubMed     Abstract available


  304. MEI CY, Wu H, Wang Y, Wang ZY, et al
    First detection of the multiresistance gene cfr in Escherichia coli from retail vegetables, China.
    Int J Antimicrob Agents. 2021;57:106348.
    PubMed    


  305. MBHELE N, Chimukangara B, Gordon M
    HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Int J Antimicrob Agents. 2021;57:106343.
    PubMed     Abstract available


  306. WANG X, Ling Z, Sun N, Liu Y, et al
    Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk.
    Int J Antimicrob Agents. 2021;57:106332.
    PubMed     Abstract available


  307. NGUYEN HT, Venter H, Veltman T, Williams R, et al
    In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens.
    Int J Antimicrob Agents. 2021;57:106323.
    PubMed     Abstract available


  308. MUSHTAQ S, Garello P, Vickers A, Woodford N, et al
    Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Int J Antimicrob Agents. 2021;57:106318.
    PubMed     Abstract available


    April 2021
  309. KOSTYANEV T, Xavier BB, Garcia-Castillo M, Lammens C, et al
    Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study.
    Int J Antimicrob Agents. 2021 Apr 19:106345.
    PubMed     Abstract available


  310. HUANG PH, Cheng YH, Chen WY, Juan CH, et al
    Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021 Apr 14:106342.
    PubMed     Abstract available


  311. CREMET L, Leroy AG, Muller D, Delanou S, et al
    Antibiotic Resistance Heterogeneity and LasR Diversity within Pseudomonas aeruginosa Populations from Pneumonia in Intensive Care Unit Patients.
    Int J Antimicrob Agents. 2021 Apr 12:106341.
    PubMed     Abstract available


  312. SCUDELLER L, Righi E, Chiamenti M, Bragantini D, et al
    Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Int J Antimicrob Agents. 2021 Apr 12:106344.
    PubMed     Abstract available


  313. TANG SSL, Chee E, Teo JQ, Chlebicki MP, et al
    Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
    Int J Antimicrob Agents. 2021 Apr 12:106340.
    PubMed     Abstract available


  314. KLEIN S, Boutin S, Heeg K, Zanger P, et al
    Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012-2018.
    Int J Antimicrob Agents. 2021;57:106312.
    PubMed     Abstract available


  315. HERRERA M, Gregorio SD, Haim MS, Posse G, et al
    Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
    Int J Antimicrob Agents. 2021;57:106304.
    PubMed     Abstract available


    March 2021
  316. BONNIN RA, Girlich D, Jousset AB, Emeraud C, et al
    Genomic analysis of VIM-2-producing Enterobacter hormaechei subsp. steigerwaltii.
    Int J Antimicrob Agents. 2021;57:106285.
    PubMed     Abstract available


  317. NI M, Zhao L, Zhang WJ, Ma JW, et al
    Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
    Int J Antimicrob Agents. 2021;57:106281.
    PubMed     Abstract available


  318. JOHNSON MG, Bruno C, Castanheira M, Yu B, et al
    Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Int J Antimicrob Agents. 2021;57:106278.
    PubMed     Abstract available


  319. VAN BILSEN WPH, van Dulm E, Matser A, Linde I, et al
    High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
    Int J Antimicrob Agents. 2021;57:106276.
    PubMed     Abstract available


  320. BALANDIN B, Ballesteros D, Ruiz de Luna R, Lopez-Vergara L, et al
    Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Int J Antimicrob Agents. 2021;57:106270.
    PubMed     Abstract available


  321. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
    Int J Antimicrob Agents. 2021;57:106257.
    PubMed     Abstract available


  322. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
    Int J Antimicrob Agents. 2021;57:106258.
    PubMed     Abstract available


    February 2021
  323. HERNANDEZ-GARCIA M, Garcia-Fernandez S, Garcia-Castillo M, Melo-Cristino J, et al
    Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Int J Antimicrob Agents. 2021;57:106259.
    PubMed     Abstract available


  324. CHERNOVA OA, Chernov VM, Mouzykantov AA, Baranova NB, et al
    Antimicrobial drug resistance mechanisms among Mollicutes.
    Int J Antimicrob Agents. 2021;57:106253.
    PubMed     Abstract available


  325. XU Q, Sheng Z, Hao M, Jiang J, et al
    RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021;57:106251.
    PubMed     Abstract available


  326. LOMBARDI F, Giacomelli A, Armenia D, Lai A, et al
    Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
    Int J Antimicrob Agents. 2021;57:106252.
    PubMed     Abstract available


  327. GOMEZ-JUNYENT J, Murillo O, Yu HH, Azad MAK, et al
    In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Int J Antimicrob Agents. 2021;57:106246.
    PubMed     Abstract available


    January 2021
  328. PICCIRILLI A, Segatore B, Brisdelli F, Amicosante G, et al
    Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1(Q119X) mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales.
    Int J Antimicrob Agents. 2021;57:106228.
    PubMed     Abstract available


  329. HUANG L, Cao M, Hu Y, Zhang R, et al
    Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China.
    Int J Antimicrob Agents. 2021;57:106226.
    PubMed     Abstract available


  330. FREITAS AR, Pereira AP, Novais C, Peixe L, et al
    Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
    Int J Antimicrob Agents. 2021;57:106227.
    PubMed     Abstract available


  331. OUCHAR MAHAMAT O, Kempf M, Lounnas M, Tidjani A, et al
    Epidemiology and prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa.
    Int J Antimicrob Agents. 2021;57:106203.
    PubMed     Abstract available


    August 2020
  332. IANNACCONE M, Boattini M, Bianco G, Cavallo R, et al
    Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2020;56:106066.
    PubMed    


  333. ANDRE-GARNIER E, Hingrat QL, Marcelin AG, Reliquet V, et al
    Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
    Int J Antimicrob Agents. 2020;56:106039.
    PubMed    


    July 2020
  334. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available


  335. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available


  336. MARTINS WMBS, Seco BMS, Sampaio JLM, Sands K, et al
    Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1.
    Int J Antimicrob Agents. 2020;56:106042.
    PubMed    


  337. HSU CY, Chen FJ, Huang WC, Liao YC, et al
    Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan.
    Int J Antimicrob Agents. 2020;56:105996.
    PubMed    


  338. FURLAN JPR, Savazzi EA, Stehling EG
    Widespread high-risk clones of multidrug-resistant extended-spectrum beta-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments.
    Int J Antimicrob Agents. 2020;56:106040.
    PubMed     Abstract available


  339. PEREZ-VAZQUEZ M, Sola-Campoy PJ, Zurita AM, Avila A, et al
    Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
    Int J Antimicrob Agents. 2020;56:106026.
    PubMed     Abstract available


  340. SANTORO MM, Fornabaio C, Malena M, Galli L, et al
    Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Int J Antimicrob Agents. 2020;56:106027.
    PubMed     Abstract available


  341. GAURAV A, Kothari A, Omar BJ, Pathania R, et al
    Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
    Int J Antimicrob Agents. 2020;56:106022.
    PubMed     Abstract available


  342. BARBOSA F, Pinto E, Kijjoa A, Pinto M, et al
    Targeting antimicrobial drug resistance with marine natural products.
    Int J Antimicrob Agents. 2020;56:106005.
    PubMed     Abstract available


  343. WILLCOCKS SJ, Cia F, Francisco AF, Wren BW, et al
    Revisiting aminocoumarins for the treatment of melioidosis.
    Int J Antimicrob Agents. 2020;56:106002.
    PubMed     Abstract available


  344. CHEN L, Han D, Tang Z, Hao J, et al
    Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine.
    Int J Antimicrob Agents. 2020;56:105993.
    PubMed     Abstract available


  345. KAVANAUGH LG, Flanagan JN, Steck TR
    Reciprocal antibiotic collateral sensitivity in Burkholderia multivorans.
    Int J Antimicrob Agents. 2020;56:105994.
    PubMed     Abstract available


  346. DOGAN O, Yesilkaya A, Menekse S, Guler O, et al
    Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Int J Antimicrob Agents. 2020;56:105992.
    PubMed     Abstract available


  347. NOEL A, Attwood M, Bowker K, MacGowan A, et al
    The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
    Int J Antimicrob Agents. 2020;56:105985.
    PubMed     Abstract available


  348. STRAZZULLA A, Iordache L, de Pontfarcy A, Pitsch A, et al
    beta-Lactam allergy and risk of multidrug-resistant bacteria in the intensive care unit: A cohort study.
    Int J Antimicrob Agents. 2020;56:105979.
    PubMed     Abstract available


  349. CAI T, Tamanini I, Mattevi D, Verze P, et al
    Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
    Int J Antimicrob Agents. 2020;56:105935.
    PubMed     Abstract available


  350. PERALES C
    Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
    Int J Antimicrob Agents. 2020;56:105562.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.